Skip to main content
Neurospine logoLink to Neurospine
. 2026 Oct 31;23(4):969–978. doi: 10.14245/ns.2551772.886

Outcomes Associated With Postoperative Dexamethasone Use After Adult Spinal Deformity Surgery

Anthony M Price 1, Barbara Buccilli 2, Nathan Fredricks 3,4, Sean O’Leary 3,4,*, Soren Jonzzon 1, Christopher M Bonfield 1, Scott L Zuckerman 1, Daniel Jupiter 5,6
PMCID: PMC13745926  PMID: 43000808

Abstract

Objective

Dexamethasone is commonly prescribed following adult spinal deformity (ASD) surgery; however, dexamethasone’s immunosuppressive effects on clinical outcomes in ASD surgery remain unclear. This study sought to: assess the effects of postoperative dexamethasone after ASD surgery, and evaluate the potential association between postoperative dexamethasone and complications.

Methods

This TriNetX study identified adults who underwent ASD surgery from 2009–2024. Outcomes were explored at 30-day, 90-day, and 1-year time points among patients with any systemic dexamethasone exposure within 7 days of surgery. Primary outcomes included wound infection, sepsis, and perioperative hematoma. Secondary outcomes included respiratory failure, delirium, new-onset diabetes, and in-hospital mortality. Propensity score matching (PSM) and logistic regression assessed associations.

Results

After PSM, 42,472 patients were included in both the dexamethasone and control cohorts. At 30 days, dexamethasone exposure was associated with higher odds of wound infection. At 90 days, these associations included elevated risks for wound infection, respiratory failure, delirium, and sepsis. By 1 year, dexamethasone use remained significantly associated with wound infection, delirium, and respiratory failure, however, hospital-recorded mortality was lower in the dexamethasone cohort.

Conclusion

In this large cohort, postoperative dexamethasone exposure was associated with increased risks of infectious and hospital-based complications, including wound infection. These findings support the need for prospective studies to define safe perioperative protocols in complex spine surgery.

Keywords: Adult spinal deformity, Dexamethasone, Complications, Infection, Postoperative care, Steroids

INTRODUCTION

Symptomatic adult spinal deformity (ASD) is increasingly recognized as a major health issue, with prevalence estimates up to 32% in the general adult population and up to 68% in elderly individuals [1]. Approximately 28 million Americans over age 65 are estimated to have an ASD diagnosis [2]. Although only a fraction require surgery, operative rates are rising due to an aging population and advances in surgical techniques, with Medicare data showing a 4-fold increase in ASD surgeries from 2000 to 2010 [2]. Despite these improvements, ASD surgery remains associated with significant perioperative risk, with 30-day complication rates reported at 30%–40% and 30-day in-hospital mortality around 0.5% [3].

ASD surgery may require multilevel osteotomies, long-segment instrumentation, and significant intraoperative time, all of which increase susceptibility to medical and surgical complications. Perioperative optimization protocols increasingly incorporate corticosteroids like dexamethasone to reduce airway edema, postoperative nausea, and systemic inflammation [4-6]. Dexamethasone is often given for new postoperative radiculopathies, which can occur in up to 9.4% of patients undergoing ASD surgery [7]. Moreover, dexamethasone has been shown to significantly improve postoperative pain management and reduce the need for opioid analgesics [8,9].

Though dexamethasone may help postoperative pain and/or new radiculopathy, its immunosuppressive effects may increase the risk of infection, poor wound healing, and other systemic complications [5,10]. In diabetic patients, it may also cause hyperglycemia and related sequelae [5]. Additionally, its impact on neurocognitive and pulmonary outcomes, particularly in complex spine populations, remains incompletely understood or characterized by the existing literature. Because of the increased surgical and medical complexity of many ASD patients, the negative impacts of dexamethasone therapy need to be carefully considered and further analyzed.

Thus, as surgical techniques advance, it is important to maximize perioperative protocols for improved patient outcomes. Given the dual potential for benefit and harm with dexamethasone use in ASD surgery, the current study aimed to evaluate the association between the use of dexamethasone and the incidence of early and long-term postoperative complications.

MATERIALS AND METHODS

1. Data Source

This study was conducted using the TriNetX Research Network (TriNetX, USA; https://live.trinetx.com), a global database that aggregates deidentified electronic health records (EHRs) from 110 healthcare organizations and over 140 million patients. In accordance with ethical and legal requirements to protect patient privacy, individual healthcare organizations within TriNetX are not identifiable. As the study exclusively accessed deidentified data, it qualifies as non-human subjects research and is exempt from institutional review board under 45 CFR 46.104(d)(4). Institutional requirements for exempt status determination were followed. This research was supported in part by a UTMB ITS Clinical and Translational Science Award (UL1 TR001439) from NIH/NCATS. TriNetX updates its datasets daily, and clinical information is systematically coded according to the International Classification of Diseases, 10th Revision (ICD-10).

2. Study Design

Patients were included if they were aged 40 years or older and underwent ASD surgery between January 1, 2009, and January 1, 2024, allowing for a full 15-year period with a minimum of one year of postoperative follow-up (Fig. 1). Eligibility required at least one documented ICD-10 diagnosis of spinal deformity, including scoliosis (M41.X), kyphosis/lordosis (M40.0–M40.5), postlaminectomy deformity (M96.20–M96.89), postoperative musculoskeletal disorder (M96.89), or complication or acquired spinal deformities (M43.X). The code M96.1 (postlaminectomy syndrome) was not included, as it typically reflects radiculopathy or pain rather than structural deformity.

Fig. 1.

Fig. 1.

Study design flowchart illustrating 7-day postoperative dexamethasone exposure and the associated 30-day, 90-day, and 1-year follow-up intervals after adult spinal deformity surgery. PSM, propensity score matching; Dex, dexamethasone; Exp, exposure; F/U, follow-up.

Patients were excluded if they had a history of chronic corticosteroid use prior to surgery (Z79.52). To improve cohort specificity, we excluded non-degenerative spinal etiologies where possible, including traumatic vertebral fractures (S12., S22.0, S32.0–S32.1), spinal neoplasms (C41.2, C72.0, C79.51, D16.6, D32.1, D33.4), spinal infections, including vertebral osteomyelitis and discitis (M46.2–M46.4), and congenital or idiopathic scoliosis (Q67.5, Q76.3, M41.0–M41.2).

3. Procedure Codes and Diagnosis Criteria

ASD surgeries were identified using a comprehensive set of Current Procedural Terminology (CPT) codes based on prior studies and American Academy of Professional Coders coding recommendations for spinal deformity [11-15]. The procedure codes used in the present query included anterior spinal osteotomies (CPT 22220, 22222, 22224, and 22226); posterior arthrodesis for spinal deformity (22800 [up to 6 vertebral segments], 22802 [7–12 vertebral segments], and 22804 [13 or more vertebral segments]); kyphectomy (22818 [1–2 vertebral segments] and 22819 [3 or more vertebral segments]); spinal instrumentation and fixation (22840 [posterior nonsegmental instrumentation], 22841 [internal spinal fixation by wiring of spinous processes], 22848 [pelvic fixation], and 22849 [reinsertion of a spinal fixation device]); exploration of spinal fusion (22830); and interbody biomechanical device procedures (22851, 22853, 22854, and 22859). CPT 22851, the historical code for application of an intervertebral biomechanical device to a vertebral defect or interspace, was deleted effective January 1, 2017 [16,17]. The query also included CPT 22853 (interbody biomechanical device placement into an intervertebral disc space in conjunction with interbody arthrodesis), CPT 22854 (intervertebral biomechanical device placement into a vertebral corpectomy defect in conjunction with interbody arthrodesis), and CPT 22859 (intervertebral biomechanical device placement into an intervertebral disc space or vertebral body defect without interbody arthrodesis), thereby including the interbody-device codes introduced during the 2017 coding transition [16,17]. CPT code definitions and codingera changes were verified using the American Medical Association Current Procedural Terminology code set and Centers for Medicare & Medicaid Services coding documentation [16,17].

4. Exposure Variable: Dexamethasone

Patients were categorized based on their exposure to systemic dexamethasone postoperatively. The dexamethasone group included patients who received any instance of systemic dexamethasone (oral or intravenous) exposure within 7 days of surgery. The nondexamethasone group comprised patients who received no dexamethasone in the same window and had no prior chronic steroid exposure. Medication exposure was determined using RxNorm drug concepts. Timing was anchored to the index surgery date to ensure only postoperative exposures were captured.

5. Outcomes

Outcomes evaluated were postoperative complications occurring between the day of surgery and 30 days, 90 days, and 1 year after surgery. Primary outcomes included wound infection (T81.4 – infection following a procedure), sepsis (A41 – other sepsis, R65.2 – severe sepsis), perioperative hemorrhage or hematoma (M96.81 – hemorrhage and hematoma of a musculoskeletal structure complicating a procedure). Secondary outcomes included respiratory failure (J96), delirium (F05 – delirium due to known physiological condition), new-onset diabetes or hyperglycemia (E08–E13), and in-hospital mortality (captured through EHR discharge status).

6. Propensity Score Matching and Statistics

Propensity score matching (PSM; nearest neighbor with caliper 0.1 standard deviation) was performed using a multivariate logistic regression model to balance baseline characteristics between the groups, including age, sex, ethnicity, and relevant comorbidities such as type 2 diabetes mellitus (E11), chronic kidney disease (N18), asthma (J45), chronic obstructive pulmonary disease (J44), chronic ischemic heart disease (I25), heart failure (I50), and hypertension (I10). Obesity and body mass index were included using ICD-10 codes E66 and Z68, respectively. Smoking status was captured using tobacco use (Z72.0) and nicotine dependence (F17.2). Surgical variability was matched for by including variables for high-complexity procedures, including long fusion (CPT 22800-22804 – spinal fusion involving up to 6, 12, and 13 or more vertebral segments), pelvic fixation (CPT 22848 – pelvic fixation with instrumentation), osteotomy (CPT 22224–22226 – anterior-based osteotomies), and intervertebral device (CPT 22854 for with arthrodesis, 22859 for without arthrodesis). Other common perioperative medications were also matched for, including gabapentin (RxNorm 25480), pregabalin (RxNorm 187832), ketorolac (RxNorm 3498), and diazepam (RxNorm 3016). Due to limitations in the TriNetX Research environment, these medications could only be matched based on their presence in the record prior to or on the index date and not based on confirmed postoperative timing.

All outcomes were assessed using logistic regression, leveraging TriNetX’s timestamped encounter and diagnosis data. Absolute risk differences (ARDs) were measured to allow for comparison of effect size between cohorts for a given outcome. Logistic regression was used to estimate the odds ratios (ORs) of binary outcomes, including wound infection, sepsis, respiratory failure, delirium, perioperative hematoma, new-onset diabetes, and in-hospital mortality, associated with dexamethasone exposure. The 7 prespecified clinical outcomes constituted the multiple-testing family within each follow-up interval. Because the 30-day, 90-day, and 1-year analyses represented distinct clinically relevant postoperative periods and were interpreted separately, Bonferroni correction was applied independently at each interval. The family-wise significance level was therefore calculated as 0.05/7=0.00714, and 2-sided p-values <0.0071 were considered statistically significant. The same 7-outcome denominator was used at all follow-up intervals to maintain a uniform and conservative threshold. All statistical interpretation and graphical outputs, including forest plots, were performed using RStudio (ver. 2024.12.0.467; RStudio, PBC, USA) with the ‘ggplot2’ package for data visualization [18,19].

RESULTS

PSM yielded 42,472 patients in both the dexamethasone and control cohorts across the 30-day, 90-day, and 1-year follow-up intervals (Table 1). Baseline cohort characteristics before PSM are shown in Supplementary Table 1.

Table 1.

Matched baseline demographics and comorbidities with 7-day postoperative dexamethasone exposure across 30-day, 90-day, and 1-year follow-up intervals in adult spinal deformity surgery

Variable 30-Day follow-up
90-Day follow-up
1-Year follow-up
Dex (%) Non-Dex (%) SMD Dex (%) Non-Dex (%) SMD Dex (%) Non-Dex (%) SMD
No. of patients after PSM 42,472 42,472 42,472 42,472 42,472 42,472
Age at index (yr), mean ± SD 62.2 ± 11.0 62.2 ± 11.5 0.001 62.2 ± 11.0 62.2 ± 11.5 0.001 62.2 ± 11.0 62.2 ± 11.5 0.001
Sex
 Female 55.8 55.5 0.006 55.8 55.5 0.006 55.8 55.5 0.006
 Male 44.2 44.5 0.006 44.2 44.5 0.006 44.2 44.5 0.006
Ethnic
 White 82.7 83.1 0.013 82.7 83.1 0.013 82.7 83.1 0.013
 Black or African American 10.0 9.8 0.006 10.0 9.8 0.006 10.0 9.8 0.006
 Hispanic or Latino 4.0 3.9 0.003 4.0 3.9 0.003 4.0 3.9 0.003
 Asian 1.6 1.6 < 0.001 1.6 1.6 < 0.001 1.6 1.6 < 0.001
 American Indian or Alaska Native 0.6 0.5 0.004 0.6 0.5 0.004 0.6 0.5 0.004
 Native Hawaiian or Other Pacific Islander 0.3 0.2 0.009 0.3 0.2 0.009 0.3 0.2 0.009
Essential (primary) hypertension 59.3 59.3 < 0.001 59.3 59.3 < 0.001 59.3 59.3 < 0.001
Overweight and obesity 30.3 30.3 0.002 30.3 30.3 0.002 30.3 30.3 0.002
Body mass index (Z68) 33.7 33.4 0.006 33.7 33.4 0.006 33.7 33.4 0.006
Nicotine dependence 21.5 21.3 0.007 21.5 21.3 0.007 21.5 21.3 0.007
Type 2 diabetes mellitus 24.1 24.0 0.003 24.1 24.0 0.003 24.1 24.0 0.003
Asthma 15.2 15.2 0.002 15.2 15.2 0.002 15.2 15.2 0.002
Chronic ischemic heart disease 17.3 17.2 0.003 17.3 17.2 0.003 17.3 17.2 0.003
Other chronic obstructive pulmonary disease 11.0 10.8 0.004 11.0 10.8 0.004 11.0 10.8 0.004
Chronic kidney disease 9.9 9.8 0.004 9.9 9.8 0.004 9.9 9.8 0.004
Tobacco use 7.6 7.4 0.007 7.6 7.4 0.007 7.6 7.4 0.007
Heart failure 6.7 6.6 0.004 6.7 6.6 0.004 6.7 6.6 0.004
Gabapentin 48.9 48.7 0.005 48.9 48.7 0.005 48.9 48.7 0.005
Ketorolac 31.7 31.3 0.008 31.7 31.3 0.008 31.7 31.3 0.008
Diazepam 22.4 21.9 0.012 22.4 21.9 0.012 22.4 21.9 0.012
Pregabalin 15.9 15.7 0.005 15.9 15.7 0.005 15.9 15.7 0.005
Osteotomy (lumbar) 0.7 0.6 0.003 0.7 0.6 0.003 0.7 0.6 0.003

Dex, dexamethasone percentage of cohort; Non-Dex, nondexamethasone percentage of cohort; SMD, standardized mean difference; PSM, propensity score matching.

1. 30-Day Follow-up Outcomes With 7-Day Dexamethasone Exposure

At 30 days, dexamethasone use was associated with significantly higher odds of several complications (Table 2; Fig. 2A). These included wound infection (OR, 1.309; 95% confidence interval [CI], 1.189–1.442; p<0.001), respiratory failure (OR, 1.339; 95% CI, 1.221–1.468; p<0.001), and delirium (OR, 1.388; 95% CI, 1.152–1.672; p=0.001). No significant associations were observed for in-hospital mortality, sepsis, perioperative hematoma, or new-onset diabetes.

Table 2.

Postoperative 7-day dexamethasone exposure comparisons across 30-day, 90-day, and 1-year follow-up intervals in adult spinal deformity surgery after propensity score matching: odds ratios, 95% confidence intervals, and p-values

Complication 30-Day follow-up
90-Day follow-up
1-Year follow-up
Dex (%) Non-Dex (%) ARD (%) OR 95% CI p-value Dex (%) Non-Dex (%) ARD (%) OR 95% CI p-value Dex (%) Non-Dex (%) ARD (%) OR 95% CI p-value
Delirium 0.6 0.5 0.2 1.388 1.152–1.672 0.001* 0.8 0.6 0.2 1.422 1.204–1.679 < 0.001* 1.0 0.8 0.2 1.289 1.117–1.487 0.001*
Mortality 0.4 0.5 -0.1 0.815 0.670–0.992 0.041 0.9 1.0 -0.1 0.878 0.765–1.007 0.063 1.8 2.3 -0.4 0.808 0.734–0.888 < 0.001*
New-onset diabetes 0.5 0.4 0.1 1.107 0.876–1.400 0.394 0.8 0.8 0 0.961 0.806–1.146 0.661 1.9 2.1 -0.1 0.927 0.828–1.038 0.190
Perioperative hematoma 0.01 0.01 0 0.947 0.497–1.805 0.869 - - - - - - - - - - - -
Respiratory failure 2.5 1.9 0.6 1.339 1.221–1.468 < 0.001* 3.1 2.4 0.7 1.290 1.187–1.401 < 0.001* 4.3 3.5 0.8 1.241 1.157–1.331 < 0.001*
Sepsis 1.3 1.1 0.1 1.111 0.982–1.257 0.095 1.9 1.7 0.3 1.160 1.047–1.284 0.004* 2.9 2.6 0.3 1.105 1.018–1.200 0.017
Wound infection 2.3 1.8 0.5 1.309 1.189–1.442 < 0.001* 3.5 2.6 0.9 1.360 1.257–1.472 < 0.001* 4.1 3.1 1.0 1.327 1.234–1.428 < 0.001*

Dex, dexamethasone percentage of cohort with outcome; Non-Dex, nondexamethasone percentage of cohort with outcome; ARD, absolute risk difference; OR, odds ratio; CI, confidence interval.

*

Statistical significance was defined as p<0.0071 after Bonferroni correction.

Fig. 2.

Fig. 2.

Forest plots: postoperative dexamethasone exposure comparisons across 30-day (A), 90-day (B), and 1-year (C) follow-up intervals in adult spinal deformity surgery. Dex, dexamethasone.

2. 90-Day Follow-up Outcomes With 7-Day Dexamethasone Exposure

At 90 days, dexamethasone exposure remained associated with significantly increased odds of several complications (Table 2; Fig. 2B), including delirium (OR, 1.422; 95% CI, 1.204–1.679; p<0.001), respiratory failure (OR, 1.290; 95% CI, 1.187–1.401; p<0.001), wound infection (OR, 1.360; 95% CI, 1.257–1.472; p<0.001), and sepsis (OR, 1.160; 95% CI, 1.047–1.284; p=0.004).

3. 1-Year Follow-up Outcomes With 7-Day Dexamethasone Exposure

At 1 year, dexamethasone exposure remained associated with significantly higher odds of several complications (Table 2; Fig. 2C), including delirium (OR, 1.289; 95% CI, 1.117–1.487; p=0.001), respiratory failure (OR, 1.241; 95% CI, 1.157–1.331; p<0.001), and wound infection (OR, 1.327; 95% CI, 1.234–1.428; p<0.001). At 1 year, hospital-recorded mortality was lower in the dexamethasone cohort (OR, 0.808; 95% CI, 0.734–0.888; p<0.001). No significant associations were observed for sepsis, or new-onset diabetes following Bonferroni correction.

DISCUSSION

In this large multicenter analysis of ASD surgery patients, postoperative dexamethasone exposure was associated with significantly increased odds of wound infection, respiratory failure, sepsis, and delirium across multiple postoperative timepoints. In contrast, hospital-recorded mortality at 1 year was lower in the dexamethasone cohort. Notably, these associations persisted across multiple follow-up intervals (30-day, 90-day, and 1-year outcomes). These findings suggest that the use of postoperative dexamethasone may be associated with increased complication rates. Additionally, although many outcomes demonstrated statistical significance, the ARDs in complication rates between cohorts were often small. As such, the clinical significance of some findings must be interpreted with consideration given to the size of their real-world impact. However, because of the observational nature of this study, it is important to interpret these correlated risks with caution, and as a sign for needed future study.

While dexamethasone is known to exert potent anti-inflammatory effects, its immunosuppressive properties may predispose patients to infectious and respiratory complications, particularly in the context of prolonged surgical duration, extensive tissue dissection, and staged procedures frequently encountered in deformity correction [20,21]. Dexamethasone inhibits leukocyte migration, suppresses macrophage activation, and impairs cytokine signaling through inhibition of pathways such as nuclear factor-kappa B, thereby weakening innate immune responses critical for surgical site defense [22]. These immunosuppressive effects, compounded by steroid-induced hyperglycemia, may explain the elevated incidence of wound infections observed. Neurocognitive complications such as delirium may also arise from corticosteroid-induced disruption of neurotransmitter regulation, particularly in vulnerable elderly patients [23-26]. Collectively, these mechanisms underscore the multifactorial risks associated with dexamethasone administration following major spinal deformity correction.

Previous analysis has found varied results on the use of dexamethasone with spinal surgery procedures. Bednar et al. [27], for example, observed in a retrospective series of 1–2 level lumbar fusions that a limited perioperative dexamethasone regimen did not significantly increase the rate of postoperative infection, and 12-month fusion rates were equivalent between steroid-treated and control patients. Similarly, Fletcher et al. [28] reported that in adolescent idiopathic scoliosis patients undergoing posterior spinal fusion, postoperative dexamethasone reduced opioid requirements by 40% without an increased risk of wound dehiscence or infection. Ruska et al. [29] also found in neuromuscular scoliosis surgery that postoperative dexamethasone significantly reduced opioid use without an increase in wound complications, pulmonary events, or infection. However, in these studies, patients were younger and generally healthier, undergoing less complex procedures than the ones included in our analysis of ASD [27].

Conversely, Blume et al. [30] reported in a study of cervical myelopathy patients undergoing anterior cervical fusion that intraoperative dexamethasone was associated with a higher rate of wound infection, including one steroid-associated death from infectious complications, highlighting the potential for increased infection risk in high-risk or complex patients. Likewise, Johnson et al. [31] reported in diabetic or frail populations a heightened risk of surgical site infections when corticosteroids are used, aligning with our observations in the ASD population. Cloney et al. [21] and Tihista et al. [32] found that patients on chronic systemic corticosteroids undergoing lumbar spine surgery had significantly higher rates of postoperative complications, infections, and sepsis, suggesting that prolonged or higher-dose corticosteroid exposure may be a key driver of adverse outcomes.

An important exception to the overall complication pattern was the lower hospital-recorded mortality observed at 1 year in the dexamethasone cohort. We do not interpret this finding as evidence of a protective mortality effect. In the broader perioperative literature, dexamethasone has not demonstrated a clear overall reduction in postoperative complications or death [33]. Long-term mortality estimation in federated EHR datasets may be affected by out-of-system care and incomplete outcome capture. Accordingly, the mortality finding should be viewed as unexpected and hypothesis-generating rather than causal.

In sum, these findings highlight the critical importance of dose, duration, and patient selection when considering perioperative corticosteroid therapy. The current study extends these concerns specifically to the high-risk ASD population, where the complexity of surgery and the fragility of the patient cohort likely exacerbate corticosteroid-associated risks. Future research is needed to continue to parse out the details and distinctions that place patients at increased risk for postoperative dexamethasone complications.

While our analysis incorporated a large, multicenter dataset, these findings must be interpreted with caution in the context of inherent limitations. The most important limitation of this observational study is the potential for confounding by indication. In clinical practice, postoperative dexamethasone is prescribed for varied indications including new radiculopathy, inadequate pain control, airway or spinal edema, prolonged intubation, and systemic inflammation. These represent potential markers of postoperative complications or a tenuous clinical course. Patients receiving dexamethasone may therefore represent a cohort that is inherently at a higher baseline risk of complications that independently predict worse outcomes. While our comprehensive PSM attempted to balance groups on a number of clinical and surgical factors, we cannot definitively exclude this as a contributing factor to our observed associations. Future prospective studies with well-defined protocols for administration of dexamethasone independent of clinical indication may help to establish a clearer causal relationship between dexamethasone and the associated outcomes presented here.

Another inherent limitation lies in cohort differences after PSM. Despite using PSM to balance baseline characteristics between groups, residual confounding cannot be ruled out. These residual imbalances may reflect limitations in the matching algorithm or unmeasured confounding factors and could introduce bias in the observed associations. As such, interpretation of findings should consider the possibility of incomplete covariate adjustment. Future, prospective studies are needed to address this limitation and to further confirm the findings presented here. Additionally, although many outcomes demonstrated statistical significance, the absolute differences in complication rates between the dexamethasone and nondexamethasone groups were often small. As such, some findings, while statistically robust, may be of limited clinical significance. These findings should be interpreted within the broader clinical context and individual patient risk profiles.

The observational nature of the study excludes causal inference, and while extensive matching was employed, residual confounding remains possible. Because the present analysis focused on dexamethasone exposure within 7 days after surgery, the effects of other exposure periods could not be evaluated independently, which resulted in limitations in performing sensitivity analyses based on treatment durations.

This study did not evaluate limited preoperative and intraoperative dexamethasone exposure, which could be another confounder. However, chronic use of systemic steroids was excluded which limits the potential confounding impact. Furthermore, the timing and indication for dexamethasone administration in TriNetX may not reliably reflect clinical intent. While it was likely used for postoperative pain control, it may also have been administered for unrelated comorbidities or in response to early signs of complications, introducing potential confounding by indication.

Additionally, the absence of specific dosing regimens and the assumption of accuracy for billing codes to define outcomes may limit the precision of these findings. Because the TriNetX database does not contain information regarding institutional protocols, surgeon-specific prescribing patterns, or standardized dosing regimens, we cannot determine whether dexamethasone was administered according to institutional protocols or at surgeon discretion.

Another limitation of the study is the inability to precisely restrict the timing of adjunct medication exposure relative to the index event. In the TriNetX Research environment, medications such as gabapentin, ketorolac, and diazepam can only be matched based on availability in the record before or on the index date. This restricts the ability to match specifically on postoperative administration, which may introduce residual confounding if the use of these medications varied between groups during the immediate postoperative period. Detailed dosing information (e.g., cumulative dose, number of administrations, or route-specific dosing) is not consistently available and therefore could not be reliably quantified. Additionally, it is impossible to control for unmeasured factors such as frailty, intraoperative blood loss, or surgeon decision making. These are potential complicating factors in ASD surgery that can have a significant impact on patients and their recovery. We believe our PSM helps to minimize these differences by controlling for factors that can contribute to frailty. However, when interpreting the observed association between dexamethasone exposure and adverse outcomes, these limitations must be considered.

Further prospective trials are needed to better define optimal indications, dosing strategies, and patient populations who may benefit or be harmed by postoperative corticosteroid use. As high-dose dexamethasone has been shown to have different effects than low-dose for our outcomes of interest in previous studies, the utilization of prospective studies of both low and high doses is necessary to confirm these findings. Furthermore, younger, healthier patients at baseline may receive the analgesic benefit from dexamethasone while being naturally resistant to increased rates of delirium that affect older patients. Working to delineate the intersectionality of the various benefits and comorbid factors at play in dosing dexamethasone will help to develop precise, effective dosing regimens. Though the results here highlight potential risks correlated with dexamethasone use, causative inference would be improper. Dexamethasone is an important postoperative therapeutic, and hasty withdrawal from its use would be unwise. Future studies are needed to quantify the positive effects of 3-, 7-, and 14-day courses of postoperative dexamethasone, which may help to fill out a more complete picture of the risks and benefits associated with postoperative dexamethasone for ASD patients.

CONCLUSION

Postoperative systemic dexamethasone use in ASD surgery was consistently correlated with increased odds of several serious complications across multiple timepoints. While dexamethasone ought to remain an important adjunct for managing perioperative inflammation and nausea, its correlation with elevated risks for wound infection, particularly in complex deformity cases, warrants deeper analysis. Future, prospective neurosurgical trials may help clarify safe usage patterns, establish risk stratification frameworks, and inform evidence-based steroid stewardship protocols in complex spine surgery.

Footnotes

Conflict of Interest

The authors have nothing to disclose.

Funding/Support

This research was supported by the UTMB Institute for Translational Sciences, supported in part by a Clinical and Translational Science Award (UL1 TR001439) from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Acknowledgments

Some but not all of these findings have been presented at the CNS Annual Meeting on October 11–15, 2025 in Los Angeles, CA.

Author Contribution

Conceptualization: AMP, NF, BB, SO, SJ, CMB, SLZ, DJ; Data curation: AMP, NF, BB, SO; Formal analysis: AMP, NF, BB, SO, DJ; Methodology: AMP, NF, BB, SO, DJ; Project administration: AMP, SO, SJ, CMB, SLZ, DJ; Visualization: AMP, SO; Writing – original draft: AMP, NF, SO, SJ, CMB, SLZ, DJ; Writing – review & editing: AMP, NF, BB, SO, SJ, CMB, SLZ, DJ.

Supplementary Material

Supplementary Table 1 is available at https://doi.org/10.14245/ns.26521626.0813.

Supplementary Table 1.

Baseline demographics and comorbidities before matching for patients with 7-day postoperative dexamethasone exposure across 30-day, 90-day, and 1-year follow-up intervals in adult spinal deformity surgery

REFERENCES

  • 1.Cerpa M, Lenke LG, Fehlings MG, et al. Evolution and advancement of adult spinal deformity research and clinical care: an overview of the Scoli-RISK-1 study. Global Spine J. 2019;9(1 Suppl):8S–14S. doi: 10.1177/2192568219828729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Safaee MM, Ames CP, Smith JS. Epidemiology and socioeconomic trends in adult spinal deformity care. Neurosurgery. 2020;87:25–32. doi: 10.1093/neuros/nyz454. [DOI] [PubMed] [Google Scholar]
  • 3.Lee NJ, Kothari P, Kim JS, et al. Early complications and outcomes in adult spinal deformity surgery: an NSQIP study based on 5803 patients. Global Spine J. 2017;7:432–40. doi: 10.1177/2192568217699384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Jeyamohan SB, Kenning TJ, Petronis KA, et al. Effect of steroid use in anterior cervical discectomy and fusion: a randomized controlled trial. J Neurosurg Spine. 2015;23:137–43. doi: 10.3171/2014.12.SPINE14477. [DOI] [PubMed] [Google Scholar]
  • 5.Polderman JA, Farhang-Razi V, Van Dieren S, et al. Adverse side effects of dexamethasone in surgical patients. Cochrane Database Syst Rev. 2018;11:CD011940. doi: 10.1002/14651858.CD011940.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Siribumrungwong K, Kanjanapirom P, Dhanachanvisith N, et al. Effect of single-dose preemptive systemic dexamethasone on postoperative dysphagia and odynophagia following anterior cervical spine surgery: a double-blinded, prospective, randomized controlled trial. Clin Orthop Surg. 2022;14:253–62. doi: 10.4055/cios21139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Smith JS, Klineberg E, Lafage V, et al. Prospective multicenter assessment of perioperative and minimum 2-year postoperative complication rates associated with adult spinal deformity surgery. J Neurosurg Spine. 2016;25:1–14. doi: 10.3171/2015.11.SPINE151036. [DOI] [PubMed] [Google Scholar]
  • 8.Heesen M, Rijs K, Hilber N, et al. Effect of intravenous dexamethasone on postoperative pain after spinal anaesthesia - a systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2019;74:1047–56. doi: 10.1111/anae.14666. [DOI] [PubMed] [Google Scholar]
  • 9.Waldron NH, Jones CA, Gan TJ, et al. Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis. Br J Anaesth. 2013;110:191–200. doi: 10.1093/bja/aes431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lee JE, Stewart KO, Swain JL, et al. Association between in situ steroids and spine surgical site infections among instrumented procedures. Infect Control Hosp Epidemiol. 2023;44:1596–600. doi: 10.1017/ice.2023.28. [DOI] [PubMed] [Google Scholar]
  • 11.Katz AD, Song J, Virk S, et al. Adjunct pelvic fixation in short-to-medium segment degenerative fusion constructs independently predicts readmission and morbidity. J Craniovertebr Junction Spine. 2022;13:182–91. doi: 10.4103/jcvjs.jcvjs_60_22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pierce KE, Kapadia BH, Naessig S, et al. Validation of the ACS-NSQIP risk calculator: a machine-learning risk tool for predicting complications and mortality following adult spinal deformity corrective surgery. Int J Spine Surg. 2021;15:1210–6. doi: 10.14444/8153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ajiboye RM, Park HY, Cohen JR, et al. Demographic trends in the use of intraoperative neuromonitoring for scoliosis surgery in the United States. Int J Spine Surg. 2018;12:393–8. doi: 10.14444/5046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kothari P, Somani S, Lee NJ, et al. Thirty-day morbidity associated with pelvic fixation in adult patients undergoing fusion for spinal deformity: a propensity-matched analysis. Glob Spine J. 2017;7:39–46. doi: 10.1055/s-0036-1583946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lee NJ, Shin JI, Kothari P, et al. Incidence, impact, and risk factors for 30-day wound complications following elective adult spinal deformity surgery. Glob Spine J. 2017;7:417–24. doi: 10.1177/2192568217699378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.American Medical Association . Current Procedural Terminology (CPT®), Professional Edition. Chicago (IL): American Medical Association; 2026. [Google Scholar]
  • 17.Centers for Medicare & Medicaid Services . Baltimore (MD): Centers for Medicare & Medicaid Services; 2016. January 2017 Integrated Outpatient Code Editor (I/OCE) Specifications Version 18.0 [Internet] [cited 2025 May 11]. Available from: https://www.cms.gov/regulations-and-guidance/guidance/transmittals/2016-transmittals-items/r3674cp. [Google Scholar]
  • 18.Posit Team . Boston (MA): Posit Software; 2024. Studio: Integrated Development Environment for R [Internet] [cited 2025 May 11]. Available from: http://www.posit.co/ [Google Scholar]
  • 19.Wickham H. ggplot2: elegant graphics for data analysis [Internet] ggplot2; 2016 [cited 2025 May 11]. Available from: https://ggplot2.tidyverse.org.
  • 20.Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;353:1711–23. doi: 10.1056/NEJMra050541. [DOI] [PubMed] [Google Scholar]
  • 21.Cloney MB, Garcia RM, Smith ZA, et al. The effect of steroids on complications, readmission, and reoperation after posterior lumbar fusion. World Neurosurg. 2018;110:e526–33. doi: 10.1016/j.wneu.2017.11.030. [DOI] [PubMed] [Google Scholar]
  • 22.Groleau C, Morin SN, Vautour L, et al. Perioperative corticosteroid administration: a systematic review and descriptive analysis. Perioper Med (Lond) 2018;7:10. doi: 10.1186/s13741-018-0092-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Catic AG. Identification and management of in-hospital drug-induced delirium in older patients. Drugs Aging. 2011;28:737–48. doi: 10.2165/11592240-000000000-00000. [DOI] [PubMed] [Google Scholar]
  • 24.Schreiber MP, Colantuoni E, Bienvenu OJ, et al. Corticosteroids and transition to delirium in patients with acute lung injury. Crit Care Med. 2014;42:1480–6. doi: 10.1097/CCM.0000000000000247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Alturaymi MA, Almadhi OF, Alageel YS, et al. The association between prolonged use of oral corticosteroids and mental disorders: do steroids have a role in developing mental disorders? Cureus. 2023;15:e37627. doi: 10.7759/cureus.37627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4(Suppl 1):S94–8. doi: 10.4103/0976-500X.120975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bednar DA, Wong A, Farrokhyar F, et al. Dexamethasone perioperative coanalgesia in lumbar spine fusion: a controlled cohort study of efficacy and safety. J Spinal Disord Tech. 2015;28:E422–6. doi: 10.1097/BSD.0b013e3182a1ddd3. [DOI] [PubMed] [Google Scholar]
  • 28.Fletcher ND, Ruska T, Austin TM, et al. Postoperative dexamethasone following posterior spinal fusion for adolescent idiopathic scoliosis. J Bone Joint Surg Am. 2020;102:1807–13. doi: 10.2106/JBJS.20.00259. [DOI] [PubMed] [Google Scholar]
  • 29.Ruska T, Austin TM, Bruce RW, et al. Post-operative steroids in patients with severe cerebral palsy undergoing posterior spinal fusion. Spine Deform. 2023;11:415–22. doi: 10.1007/s43390-022-00603-8. [DOI] [PubMed] [Google Scholar]
  • 30.Blume C, Wiederhold H, Geiger M, et al. Lacking benefit of intraoperative high-dose dexamethasone in instrumented surgery for cervical spondylotic myelopathy. J Neurol Surg A Cent Eur Neurosurg. 2018;79:116–22. doi: 10.1055/s-0037-1608824. [DOI] [PubMed] [Google Scholar]
  • 31.Johnson D, McCormick B, Kim B, et al. Use of dexamethasone in the immediate postoperative period is associated with increased risk of instrumentation and surgical site complications in diabetic patients undergoing lumbar spinal fusion. Clin Spine Surg. doi: 10.1097/BSD.0000000000002031. 2026 Feb 20. doi: 10.1097/BSD.0000000000002031. [Epub] [DOI] [PubMed] [Google Scholar]
  • 32.Tihista M, Gu A, Wei C, et al. The impact of long-term corticosteroid use on acute postoperative complications following lumbar decompression surgery. J Clin Orthop Trauma. 2020;11:921–7. doi: 10.1016/j.jcot.2020.04.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Asehnoune K, Le Moal C, Lebuffe G, et al. Effect of dexamethasone on complications or all cause mortality after major non-cardiac surgery: multicentre, double blind, randomised controlled trial. BMJ. 2021;373:n1162. doi: 10.1136/bmj.n1162. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Table 1.

Baseline demographics and comorbidities before matching for patients with 7-day postoperative dexamethasone exposure across 30-day, 90-day, and 1-year follow-up intervals in adult spinal deformity surgery


Articles from Neurospine are provided here courtesy of Korean Spinal Neurosurgery Society

RESOURCES